These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31023614)

  • 1. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.
    Lionetti R; Piccolo P; Lenci I; Siciliano M; Visco-Comandini U; De Santis A; Pompili M; Milana M; Taibi C; Dell'Isola S; Montalbano M; Mastroianni C; Begini P; Garbuglia AR; Angelico M; D'Offizi G
    Ann Hepatol; 2019; 18(3):434-438. PubMed ID: 31023614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
    Hézode C; Lebray P; De Ledinghen V; Zoulim F; Di Martino V; Boyer N; Larrey D; Botta-Fridlund D; Silvain C; Fontaine H; D'Alteroche L; Leroy V; Bourliere M; Hubert-Fouchard I; Guyader D; Rosa I; Nguyen-Khac E; Fedchuk L; Akremi R; Bennai Y; Filipovics A; Zhao Y; Bronowicki JP
    Liver Int; 2017 Sep; 37(9):1314-1324. PubMed ID: 28177199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Cheng PN; Chiu YC; Chien SC; Chiu HC
    J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
    Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
    Smirne C; D'Avolio A; Bellan M; Gualerzi A; Crobu MG; Pirisi M
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00811. PubMed ID: 34152088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
    Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM
    Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
    J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
    Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
    J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
    Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2019 Sep; 82(9):693-698. PubMed ID: 31356562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
    El-Khayat H; Fouad Y; Mohamed HI; El-Amin H; Kamal EM; Maher M; Risk A
    Aliment Pharmacol Ther; 2018 Mar; 47(5):674-679. PubMed ID: 29314146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
    McCaughan GW; Thwaites PA; Roberts SK; Strasser SI; Mitchell J; Morales B; Mason S; Gow P; Wigg A; Tallis C; Jeffrey G; George J; Thompson AJ; Parker FC; Angus PW;
    Aliment Pharmacol Ther; 2018 Feb; 47(3):401-411. PubMed ID: 29205432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
    Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
    Carrai P; Morelli C; Cordone G; Romano A; Tamé M; Lionetti R; Pietrosi G; Lenci I; Piai G; Russo FP; Coppola C; Melazzini M; Montilla S; Pani L; Petraglia S; Russo P; Trotta MP; Martini S; Toniutto P;
    Transpl Int; 2017 Dec; 30(12):1253-1265. PubMed ID: 28799277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
    Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
    Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
    Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
    Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.